Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on TIZIANA LIFE SCIENCES PLC. We currently have 10 research reports from 3 professional analysts.
|16Jan17 07:00||RNS||Warrant Expiry - Reminder|
|03Jan17 07:00||RNS||Tiziana Life Sciences in-licenses NI-1201|
|16Nov16 07:00||RNS||New Data with Foralumab|
|07Nov16 12:29||RNS||Grant of options|
|29Sep16 07:00||RNS||Half-year Report|
|15Sep16 07:00||RNS||Confirmation of Capital Reduction|
|18Jul16 07:00||RNS||Tiziana acquires a unique bio-repository|
Frequency of research reports
Research reports on
TIZIANA LIFE SCIENCES PLC
TIZIANA LIFE SCIENCES PLC
04 Jan 17
Has Trumponomics scored its first success for American workers? Yesterday’s decision from Ford to cancel its planned US$1.6bn Mexico plant and instead invest US$700m in Michigan following the President-elect’s criticism of rival General Motors with the treat of a “big border tax” on compact cars re-imported from neighbouring countries, suggests maybe it has. The Dollar also celebrated yesterday’s release of strong macro data, including Maufacturing PMI, ISM and Construction figures, which powered the greenback to a 14-year high against the international basket. US stocks celebrated the news with the Dow Jones rising 175-point rise in early trading, reflecting optimism that equities will be sure fire winners in an expanding, less regulated environment as the ending of the bond market’s long-run bull becomes all but confirmed. While some of the gains were given back before the session close, all principal indices ended their first trading day of 2017 showing impressive gains particularly in telecom and healthcare with traders convinced psychological resistance to breaking Dow’s 20,000 barrier will be broken very shortly. Asia also put in a good performance, with Japan more than catching up with its neighbours following its four-day holiday weekend by putting in a gain of 2.5% driven primarily by financials and export stocks, leaving only the Hang Seng fractionally in the negative after Tuesday’s strong rise. A good batch of macro data is due for release today, with investor eyes mainly focussed on the Eurozone’s Consumer Price Index figure for December, which is expected to come out at around 1.0% (from 0.6% last time) thereby providing confirmation that the major western economies are finally returning to a phase of rising inflation. The UK will provide the BRC Shop Price Index, PMI Construction numbers for December plus November’s Consumer Credit and Mortgage Approvals, while the US is scheduled to detail MBA Mortgage Applications and FOMC Minutes. Amongst corporates, the eagerly awaited Christmas Trading Statement from Next (NXT.L) is due for release this morning along with Ryanair (RYA.L) December Passenger Figures, while earnings or updates are also anticipated from B&M European Value (BME.L) and Staffline Group (STAF.L). The FTSE-100 is seen taking its opening confidence from the overnight markets and expected to rise around 12 points in early morning trading.
17 Nov 16
"The Fed's Patrick Harker yesterday spelt out just how complex policy on interest rates has now become. Janet Yellen's own testimony this afternoon, which is seen as key to December's FOMC decision, will have to grapple with all the new uncertainties injected by the President-elect, ranging from regressive tax cuts, booming infrastructure spending, financial deregulation and cuts in federal spending. No easy task, even if the markets appear more convinced than ever that the first hike since 2006 will be delivered next month and that this will be the first of a series of such moves over the subsequent 18 or so months as inflation climbs. The recent phase of asset repricing, nevertheless, took a breather yesterday, with all principal markets making only fractional movements. The Dow Jones broke its record run to drift into the red as financials retrenched, while momentum in technology stocks meant the NASDAQ still managed to close modestly up. Asia also put in just marginal movements across the board, as oil prices went lower on weekly data detailing a large rise in inventories, while the Bank of Japan surprised traders with its plans to buy unlimited JGBs at fixed rates in its latest daily market operation. The latter, of course, being seen as it effort to ensure domestic rates do not find themselves shackled to the US T-bill's upward movements. Today, the UK is due to release retail sales figures while the CML provides mortgage lending data; Eurozone inflation numbers are also expected this morning. Clearly the principal event of the day, however, will be Janet Yellen's Testimony on Capitol Hill which is due to commence at 10:00hrs EST and likely overshadow speeches also due from the Fed's William Dudley and Lael Brainard; the US is due to release inflation, weekly jobless claims and export statistics this afternoon as well. Another busy day for UK corporates, with earnings or trading updates scheduled from the likes of CRH (CRH.L), Great Portland Estates (GPOR.L), Johnson Matthey (JMAT.L), Kier Group (KIER.L), Premier Oil (PMO.L), Royal Mail (RMG.L), Shanks (SKS.L), Ted Baker (TED.L), TT Electronics (TTG.L) and Watkin Jones (WJG.L). The FTSE-100 is expected to open virtually unchanged." - Barry Gibb, Research Analyst
N+1 Singer - Small-cap quantitative research - New momentum screen + 10 “trendy friendlies”
28 Jul 16
We present here our new momentum screen, which is intended to track the behaviour of small-cap shares experiencing the most positive technical momentum. This represents the third of our style baskets, with value and consistent growth themes already established. This is not intended to address the perennial tension between technical and fundamental analysts, merely to investigate behaviour over time. Of the 25 stocks in the basket, we have focussed on 10 which we know and believe to be particularly interesting. With the widely used dictum “the trend is your friend” in mind, we have dubbed them the “trendy friendlies”. We will monitor performance and refresh the screen in 3-4 months’ time.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Panmure Morning Note 15-02-2017
15 Feb 17
With the early January trading update having prompted us to upgrade forecasts, today’s interim results show how the group’s focus on areas such as product development and international sales are translating through to growth in both the top and bottom-line. The consistency of delivery is what impresses us, reflecting the maturity of the management team and the clarity of the longterm vision. We repeat our Buy recommendation.
N+1 Singer - Morning Song 21-02-2017
21 Feb 17
Abzena (ABZA LN) Contract bookings strong; US costs higher than expected | City of London Investment Group (CLIG LN) Earnings and interim dividend in line, some modest growth in FuM | dotdigital Group (DOTD LN) Good H1; broadening avenues of growth | Grafenia (GRA LN) Weak print volumes | Vernalis (VER LN) Interims highlight increasing Tuzistra™ scrip volume
Panmure Morning Note 20-02-2017
20 Feb 17
Chi-Med has announced the initiation of a Phase II study of savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) in China. This is a disease where patients are usually diagnosed by normal pathology (i.e. not via molecular diagnostics methods) but given that 20-30% of PSC patient show c-Met gene amplification this potentially represents a very rich patient pool for savolitinib as a highly selective and potent oral c-Met inhibitor. The continued strength of Chi-Med’s clinical momentum is further demonstrated by today’s news and we consider this represents further upside potential against our existing investment case. We repeat our Buy recommendation.
Discovering a sustainable model
21 Feb 17
We expect C4XD to begin to deliver commercially in 2017, following the shift in strategy away from fee for service in 2016. Over the next 12 months we expect C4XD to sign its first pre-clinical out-licensing deal, develop at least one more product line and sign at least one more strategic alliance. We believe this demonstration of the model will translate to a step up in value and we initiate coverage with a BUY recommendation and 129p price target.
AIPAC Phase IIb starts randomised component
15 Feb 17
Prima BioMed maintains its leadership in LAG-3 immunotherapies with the initiation of the randomised Phase IIb component of the AIPAC trial of IMP321 in breast cancer. In addition, the TACTI-Mel study of IMP321 combined with Keytruda in melanoma is expected to complete recruitment and report safety data in mid-2017, while the pipeline now includes a first-in-class Lag-3 agonist antibody. Initial efficacy data on the first 15 patients in AIPAC is also expected mid-year. We have revised development timelines for in-house and partnered LAG-3 programmes, which sees our valuation decrease to A$252m or A$0.12/share (vs A$282m or A$0.14/share).